Lung CancerNCT07146568
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
A study testing Pink and Pearl Campaign in people with Lung Cancer and Cancer of the Lung, run by Washington University School of Medicine at 1 site in United States.
Trial summary
Inspired by the ongoing Pink \& Pearl Campaign, the breast radiology service of Christian Hospital in north St. Louis County will partner with Siteman Cancer Center to pilot this campaign in its mammography clinics in order to promote awareness, referral, and completion of lung cancer screening (LCS) among eligible… Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer, Cancer of the Lung
- What is being tested?
- Pink and Pearl Campaign
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,515 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Feb 2026to 28 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Eligibility Criteria - Interventional Study
- Undergoing screening mammography at Christian Hospital
- Between the ages of 50-80 years (inclusive)
Eligibility Criteria - Survey and Interview Sub-Studies
- Part of the interventional study
- Reporting a 20 pack-year equivalent of either current smoking history or have quit in the past 15 years
- Can speak and understand English
- Not diagnosed with a serious health problem that will limit life expectancy (such as previous history of lung cancer, symptoms of lung cancer such as hemoptysis or unexplained weight loss of more than 6.8 kg (15 lb) in the previous year)
- Willing and able to get treatment if lung cancer is found
- Able to understand and willing to sign an IRB-approved written informed consent document
Eligibility Criteria - Providers
- At least 20 years of age
- Involved in the breast radiology service or referred at least one patient to the Pink \& Pearl Campaign
- Able to provide verbal consent to participate in the interview
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Barnes-Jewish Christian Hospital
St Louis, Missouri, 63136
Beryne Odeny, M.D. MPH, Ph.D., 314-362-1183, beryne@wustl.edu
Michelle V Lee, M.D., 314-454-7405, lee.michelle@wustl.edu
About this study
Inspired by the ongoing Pink \& Pearl Campaign, the breast radiology service of Christian Hospital in north St. Louis County will partner with Siteman Cancer Center to pilot this campaign in its mammography clinics in order to promote awareness, referral, and completion of lung cancer screening (LCS) among eligible women. This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening. The purpose of this study is to evaluate the effectiveness of the Pink \& Pearl Campaign in improving LCS uptake among LCS-eligible women undergoing mammography at Christian Hospital. This evaluation is grounded in the Integrated Screening Action Model that depicts individual- and environmental-level influences on the screening behavior process. Using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, our specific aims for this proposal are to: a) assess whether the Pink \& Pearl Campaign increases referrals and uptake/completion of LCS among LCS-eligible women undergoing screening mammography; b) determine median time-to-screening after referral to LCS; and c) evaluate individual and health system factors influencing LCS uptake and implementation outcomes of the campaign. These implementation outcomes will help identify whether the campaign was put in place successfully or not. This proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like LCS.
- Conditions
- Lung Cancer, Cancer of the Lung
- Being tested
- Pink and Pearl Campaign
- Keywords
- Lung cancer screening (LCS), Pink and Pearl Campaign, Breast cancer screening (BCS), Low-dose computed tomography (LDCT), Smoking history, Health disparities, Screening behavior, Feasibility, Acceptability, Appropriateness
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pink and Pearl CampaignOther
This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening.
| Study group | Role | What they receive |
|---|---|---|
| Participants - scheduled for mammography and eligible for LCS | Experimental | All women coming in for breast cancer screening will be assessed for LCS eligibility using a screening questionnaire administered by mammography technicians. Patients who are determined to be eligible for LCS will be asked by the mammography technician if they will opt into being contacted by the nurse navigator, who will facilitate their referral to primary care to schedule a LCS appointment at Siteman Cancer Center. Receives: Other: Pink and Pearl Campaign |
| Providers | No intervention | Providers in the breast radiology service who referred women to LCS. Investigators will gather information on the feasibility, acceptability, and appropriateness of the Pink and Pearl project. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of women referred from the breast radiology service who successfully complete LCS 6-months post-Pink & Pearl implementation
The investigators will compare the baseline prevalence of LCS among women undergoing BCS to the prevalence of LCS among women undergoing BCS 6 months after implementation of the Pink \& Pearl Campaign.
Measured: At 6 months
Secondary outcomes (2)
Median time-to-screening
The investigators will compare differences in time-to-lung cancer screening across heterogenous populations
Measured: At 6 months
Acceptability of Pink & Pearl Campaign
Defined as the perception that the campaign is agreeable or satisfactory
Measured: At 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2025
- Study start23 Feb 2026
- Primary completion28 Feb 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 5,515 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Beryne Odeny, M.D., MPH, Ph.D., Principal investigator, Washington University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07146568
- Sponsor's protocol ID
- 202508075
- Status last verified
- Aug 2026
- First submitted
- 21 Aug 2025
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Plan to share results interpretations.
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
- ClinicalTrials.gov ID
- NCT07146568
- Acronym / sponsor ID
- 202508075
- Conditions
- Lung Cancer, Cancer of the Lung
- Keywords
- Lung cancer screening (LCS), Pink and Pearl Campaign, Breast cancer screening (BCS), Low-dose computed tomography (LDCT), Smoking history, Health disparities, Screening behavior, Feasibility
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 5,515 participants (estimated)
- Lead sponsor
- Washington University School of MedicineUniversity, hospital or other
- Study start
- 23 Feb 2026 (actual)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 28 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Inspired by the ongoing Pink \& Pearl Campaign, the breast radiology service of Christian Hospital in north St. Louis County will partner with Siteman Cancer Center to pilot this campaign in its mammography clinics in order to promote awareness, referral, and completion of lung cancer screening (LCS) among eligible women. This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening. The purpose of this study is to evaluate the effectiveness of the Pink \& Pearl Campaign in improving LCS uptake among LCS-eligible women undergoing mammography at Christian Hospital. This evaluation is grounded in the Integrated Screening Action Model that depicts individual- and environmental-level influences on the screening behavior process. Using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, our specific aims for this proposal are to: a) assess whether the Pink \& Pearl Campaign increases referrals and uptake/completion of LCS among LCS-eligible women undergoing screening mammography; b) determine median time-to-screening after referral to LCS; and c) evaluate individual and health system factors influencing LCS uptake and implementation outcomes of the campaign. These implementation outcomes will help identify whether the campaign was put in place successfully or not. This proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like LCS.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Participants - scheduled for mammography and eligible for LCS | Experimental | Other: Pink and Pearl CampaignAll women coming in for breast cancer screening will be assessed for LCS eligibility using a screening questionnaire administered by mammography technicians. Patients who are determined to be eligible for LCS will be asked by the mammography technician if they will opt into being contacted by the nurse navigator, who will facilitate their referral to primary care to schedule a LCS appointment at Siteman Cancer Center. |
| Providers | No intervention | –Providers in the breast radiology service who referred women to LCS. Investigators will gather information on the feasibility, acceptability, and appropriateness of the Pink and Pearl project. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pink and Pearl CampaignThis campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening. | Other | Participants - scheduled for mammography and eligible for LCS |
Primary outcome
Proportion of women referred from the breast radiology service who successfully complete LCS 6-months post-Pink & Pearl implementation
Time frame: At 6 months
The investigators will compare the baseline prevalence of LCS among women undergoing BCS to the prevalence of LCS among women undergoing BCS 6 months after implementation of the Pink \& Pearl Campaign.
2 secondary outcomes
Median time-to-screening
Time frame: At 6 months
Acceptability of Pink & Pearl Campaign
Time frame: At 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
- Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of MedicineLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Plan to share results interpretations.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Beryne Odeny, M.D., MPH, Ph.D. principal investigator
Washington University School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pink and Pearl Campaign in people with Lung Cancer and Cancer of the Lung, run by Washington University School of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Beryne Odeny, M.D., MPH, Ph.D. (314-362-1183, beryne@wustl.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of women referred from the breast radiology service who successfully complete LCS 6-months post-Pink & Pearl implementation (time frame: At 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.